Table of Contents

1 Study Coverage

• 1.1 Cefprozil Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Cefprozil Market Size Growth Rate by Product
  • 1.4.2 Anhydrous
  • 1.4.3 Monohydrate
• 1.5 Market by End User
  • 1.5.1 Global Cefprozil Market Size Growth Rate by End User
  • 1.5.2 Pharyngitis/tonsillitis
  • 1.5.3 Otitis Media
  • 1.5.4 Acute Sinusitis
  • 1.5.5 Secondary Bacterial Infection
  • 1.5.6 Uncomplicated Skin
  • 1.5.7 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Cefprozil Market Size
  • 2.1.1 Global Cefprozil Revenue 2014-2025
  • 2.1.2 Global Cefprozil Sales 2014-2025
• 2.2 Cefprozil Growth Rate by Regions
  • 2.2.1 Global Cefprozil Sales by Regions
  • 2.2.2 Global Cefprozil Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Cefprozil Sales by Manufacturers
  • 3.1.1 Cefprozil Sales by Manufacturers
  • 3.1.2 Cefprozil Sales Market Share by Manufacturers
  • 3.1.3 Global Cefprozil Market Concentration Ratio (CR5 and HHI)
• 3.2 Cefprozil Revenue by Manufacturers
  • 3.2.1 Cefprozil Revenue by Manufacturers (2014-2019)
  • 3.2.2 Cefprozil Revenue Share by Manufacturers (2014-2019)
• 3.3 Cefprozil Price by Manufacturers
• 3.4 Cefprozil Manufacturing Base Distribution, Product Types
  • 3.4.1 Cefprozil Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Cefprozil Product Type
  • 3.4.3 Date of International Manufacturers Enter into Cefprozil Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Cefprozil Sales by Product
• 4.2 Global Cefprozil Revenue by Product
• 4.3 Cefprozil Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Cefprozil Breakdown Data by End User

6 North America

• 6.1 North America Cefprozil by Countries
  • 6.1.1 North America Cefprozil Sales by Countries
  • 6.1.2 North America Cefprozil Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Cefprozil by Product
• 6.3 North America Cefprozil by End User

7 Europe

• 7.1 Europe Cefprozil by Countries
  • 7.1.1 Europe Cefprozil Sales by Countries
  • 7.1.2 Europe Cefprozil Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Cefprozil by Product
• 7.3 Europe Cefprozil by End User

8 Asia Pacific

• 8.1 Asia Pacific Cefprozil by Countries
  • 8.1.1 Asia Pacific Cefprozil Sales by Countries
  • 8.1.2 Asia Pacific Cefprozil Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Cefprozil by Product
• 8.3 Asia Pacific Cefprozil by End User

9 Central & South America

• 9.1 Central & South America Cefprozil by Countries
  • 9.1.1 Central & South America Cefprozil Sales by Countries
  • 9.1.2 Central & South America Cefprozil Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Cefprozil by Product
• 9.3 Central & South America Cefprozil by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Cefprozil by Countries
  • 10.1.1 Middle East and Africa Cefprozil Sales by Countries
  • 10.1.2 Middle East and Africa Cefprozil Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Cefprozil by Product
• 10.3 Middle East and Africa Cefprozil by End User

11 Company Profiles

• 11.1 Orchid
  • 11.1.1 Orchid Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Orchid Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Orchid Cefprozil Products Offered
  • 11.1.5 Orchid Recent Development
• 11.2 Taj Pharma
  • 11.2.1 Taj Pharma Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Taj Pharma Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Taj Pharma Cefprozil Products Offered
  • 11.2.5 Taj Pharma Recent Development
• 11.3 Dhanuka
  • 11.3.1 Dhanuka Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Dhanuka Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Dhanuka Cefprozil Products Offered
  • 11.3.5 Dhanuka Recent Development
• 11.4 Lupin
  • 11.4.1 Lupin Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Lupin Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Lupin Cefprozil Products Offered
  • 11.4.5 Lupin Recent Development
• 11.5 Alkem
  • 11.5.1 Alkem Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Alkem Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Alkem Cefprozil Products Offered
  • 11.5.5 Alkem Recent Development
• 11.6 Corden Pharma
  • 11.6.1 Corden Pharma Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Corden Pharma Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Corden Pharma Cefprozil Products Offered
  • 11.6.5 Corden Pharma Recent Development
• 11.7 Aurobindo
  • 11.7.1 Aurobindo Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Aurobindo Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Aurobindo Cefprozil Products Offered
  • 11.7.5 Aurobindo Recent Development
• 11.8 Covalent
  • 11.8.1 Covalent Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Covalent Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Covalent Cefprozil Products Offered
  • 11.8.5 Covalent Recent Development
• 11.9 TEVA GROUP
  • 11.9.1 TEVA GROUP Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 TEVA GROUP Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 TEVA GROUP Cefprozil Products Offered
  • 11.9.5 TEVA GROUP Recent Development
• 11.10 Hetero Drugs
  • 11.10.1 Hetero Drugs Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Hetero Drugs Cefprozil Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Hetero Drugs Cefprozil Products Offered
  • 11.10.5 Hetero Drugs Recent Development
• 11.11 Qilu Antibiotics
• 11.12 Dongying Pharma
• 11.13 Union Chempharma
• 11.14 Huafangpharm
• 11.15 Topfond

12 Future Forecast

• 12.1 Cefprozil Market Forecast by Regions
  • 12.1.1 Global Cefprozil Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Cefprozil Revenue Forecast by Regions 2019-2025
• 12.2 Cefprozil Market Forecast by Product
  • 12.2.1 Global Cefprozil Sales Forecast by Product 2019-2025
  • 12.2.2 Global Cefprozil Revenue Forecast by Product 2019-2025
• 12.3 Cefprozil Market Forecast by End User
• 12.4 North America Cefprozil Forecast
• 12.5 Europe Cefprozil Forecast
• 12.6 Asia Pacific Cefprozil Forecast
• 12.7 Central & South America Cefprozil Forecast
• 12.8 Middle East and Africa Cefprozil Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Cefprozil Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Cefprozil is a semi-synthetic broad-spectrum cephalosporin antibiotic, and it is a second-generation cephalosporin type antibiotic. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections. It comes as a tablet and as a liquid suspension.
Due to the manufacture policy, the Cefprozil industry is relative concentrated, the manufacture technology is relative mature.
India and China are the main production areas, India with a market share of 50.79%, China with a market share of 29.03%, China Most of the products are exported to developed countries.
The global Cefprozil market is valued at 130 million US$ in 2018 and will reach 140 million US$ by the end of 2025, growing at a CAGR of 1.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cefprozil market based on company, product type, end user and key regions.

This report studies the global market size of Cefprozil in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cefprozil in these regions.
This research report categorizes the global Cefprozil market by top players/brands, region, type and end user. This report also studies the global Cefprozil market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Orchid
Taj Pharma
Dhanuka
Lupin
Alkem
Corden Pharma
Aurobindo
Covalent
TEVA GROUP
Hetero Drugs
Qilu Antibiotics
Dongying Pharma
Union Chempharma
Huafangpharm
Topfond

Market size by Product
Anhydrous
Monohydrate
Market size by End User
Pharyngitis/tonsillitis
Otitis Media
Acute Sinusitis
Secondary Bacterial Infection
Uncomplicated Skin
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Cefprozil market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cefprozil market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cefprozil companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cefprozil submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Cefprozil are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cefprozil market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.